Alnylam Delays IND For RNAi Flu Therapy; Nastech RNAi Program Moves Forward

 
• By Pamela Taulbee

Nastech shows positive preclinical results with delivery technology for RNAi targeting influenza A.

More from Archive

More from Pink Sheet